The session will review the recent landscape of administrative, civil and criminal actions brought and penalties obtained by U.S. Attorney’s Offices and the Drug Enforcement Administration (DEA) involving violations of the Controlled Substances Act and related rules in the Code of Federal Regulations, including investigative techniques such as audits and administrative warrants the DEA regularly employs.
The webinar will also address the requirements when prescribing through Telehealth, trends in state Prescription Drug Monitoring Programs laws, applicability of medical marijuana laws to hospitals and will discuss best practices to follow for hospital pharmacies in assuring compliance with controlled substances laws.
The panel, moderated by Judith Waltz will include:
Daniel Gillen
Chief, Drug Enforcement Administration
U.S. Department of Justice
Washington, DC
William P. Keane
Partner
Farella Braun + Martel
San Francisco, CA
Natalia Mazina
Counsel
Klein, Hockel, Iezaa & Patel P.C.
San Francisco, CA
Dennis Wichern
Special Agent in Charge, DEA
U.S. Department of Justice
Washington, DC
The panelists will review practical tips for responding to such investigative techniques, and discuss the best strategies to avoid DEA audits or potential revocation/suspension of DEA registrations. To learn more and to register, visit the AHLA website.
